Many of the inflammatory analytes down-regulated during apremilast treatment in the current subset of PALACE 1 patients, including TNF-α, IL-8, IL-17, MIP-1β, and MCP-1, are over-expressed in patients with psoriasis and PsA [14–17]. Here, CCL2 is linked to psoriasis.